RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
Go back to RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 36.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.76 | 52 Week High | $66.55 | |||
| Open | $36.76 | 52 Week Low | $37.82 | |||
| Day High | $36.76 | P/E | N/A | |||
| Day Low | $36.76 | EPS | $0.00 | |||
| Volume | 1,202 | |||||
